Latest Ratios: P/E Ratio -1.9x · EV/EBITDA -10.5x · ROE -3.3%. (2017–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $58M | — | — | — | — | — | — | — |
| Enterprise Value | $-7092871 | $48M | — | — | — | — | — | — | — |
| P/E Ratio → | -1.89 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.11 | 2.30 | — | — | — | — | — | — | — |
| P/B Ratio | 0.06 | 1.31 | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | 5.01 | 106.09 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.91 | — | — | — | — | — | — | — |
| EV / EBITDA | -10.53 | 71.16 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.4% | 16.4% | 3.8% | 9.6% | 9.9% | 15.1% | 21.0% | 16.1% | 15.0% |
| Operating Margin | -2.2% | -2.2% | -5.6% | 3.2% | 4.2% | 9.6% | 13.4% | 11.9% | 5.0% |
| Net Profit Margin | -5.7% | -5.7% | -16.7% | 1.7% | 5.5% | 10.1% | 11.6% | 10.3% | 6.3% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.3% | -3.3% | -15.7% | 1.9% | 7.4% | 19.7% | 26.4% | 32.9% | 10.4% |
| ROA | -2.8% | -2.8% | -13.4% | 1.5% | 5.1% | 12.1% | 15.5% | 15.5% | 4.2% |
| ROIC | -1.2% | -1.2% | -4.9% | 3.3% | 4.5% | 15.2% | 23.4% | 28.1% | 5.6% |
| ROCE | -1.3% | -1.3% | -5.2% | 3.7% | 5.5% | 18.0% | 29.0% | 34.7% | 7.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.01 | 0.03 | 0.14 | 0.26 | 0.22 | 0.24 | 0.51 |
| Debt / EBITDA | — | — | — | 0.53 | 2.24 | 1.27 | 0.67 | 0.58 | 2.93 |
| Net Debt / Equity | — | -0.22 | -0.16 | -0.23 | -0.04 | -0.15 | 0.01 | -0.06 | 0.12 |
| Net Debt / EBITDA | -14.58 | -14.58 | — | -3.77 | -0.68 | -0.72 | 0.04 | -0.14 | 0.66 |
| Debt / FCF | — | — | — | -1.34 | — | — | — | -0.31 | 1.37 |
| Interest Coverage | -0.88 | -0.88 | — | — | 41.41 | 19.81 | 27.63 | 27.62 | 4.00 |
Net cash position: cash ($10M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.39 | 3.39 | 5.18 | 3.27 | 2.22 | 2.04 | 2.14 | 1.55 | 1.22 |
| Quick Ratio | 2.82 | 2.82 | 4.43 | 2.30 | 1.53 | 1.39 | 1.07 | 0.88 | 0.51 |
| Cash Ratio | 2.07 | 2.07 | 3.37 | 1.56 | 0.58 | 0.64 | 0.39 | 0.37 | 0.30 |
| Asset Turnover | — | 0.47 | 0.91 | 1.01 | 0.76 | 1.04 | 1.31 | 1.51 | 0.68 |
| Inventory Turnover | 4.16 | 4.16 | 8.96 | 6.60 | 4.12 | 3.54 | 2.91 | 4.41 | 1.49 |
| Days Sales Outstanding | — | 83.98 | 49.91 | 27.42 | 86.10 | 92.10 | 48.62 | 38.36 | 16.33 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | 14.2% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M |
Severe Revenue Contraction Risk
As reported in recent financial filings, BGM's P/S ratio of 0.09 and negative P/E of -1.62 suggest that the market is pricing the firm at a significant discount, likely reflecting deep skepticism regarding its ability to return to profitability following a 45.99% year-over-year revenue decline.
The current valuation multiples appear to signal that investors view the company as a distressed asset rather than a growth-oriented pharmaceutical entity. This pricing suggests that the market may be discounting the firm's future earnings potential to near zero, given the lack of a clear path to reversing the current negative operating margin trend.
Based on the company's reported figures, the gross margin of 16.39% appears insufficient to cover fixed costs, resulting in a negative operating margin of -2.25% that highlights the firm's struggle to maintain profitability in a competitive generic API and agricultural processing market.
The thin gross margin suggests that BGM lacks the pricing power typically associated with specialty pharmaceutical firms, effectively operating as a commodity processor. Investors should monitor whether this margin profile is a structural outcome of its reliance on volatile raw licorice root costs or a temporary result of recent operational inefficiencies.
According to recent financial statements, BGM maintains a $9.8 million cash position, which serves as the primary liquidity buffer against its current operational burn, though this reserve appears increasingly inadequate to support long-term strategic pivots or significant supply chain disruptions in the volatile Chinese agricultural market.
The firm's liquidity position warrants further investigation, as the absence of consistent cash flow generation may force management to rely on this limited reserve to fund ongoing administrative overhead. This vulnerability is exacerbated by the company's exposure to localized regulatory and economic shifts within the Gansu province.
As indicated by the company's product mix, the market commonly misapplies pharmaceutical valuation metrics to BGM, which obscures the reality that its financial profile more closely resembles a cyclical agricultural processor with a pharmaceutical sideline, as reported in recent operational disclosures.
Using standard pharmaceutical P/E or R&D-based valuation models for BGM is likely misleading because it ignores the cyclicality of the fertilizer and sausage casing segments. Analysts should instead focus on commodity price sensitivity and agricultural procurement cycles to better understand the firm's true operational viability.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BGM stock.
BGM Group Ltd.'s current P/E ratio is -1.9x. This places it at the 50th percentile of its historical range.
BGM Group Ltd.'s current EV/EBITDA is -10.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 71.2x.
BGM Group Ltd.'s return on equity (ROE) is -3.3%. The historical average is 10.0%.
Based on historical data, BGM Group Ltd. is trading at a P/E of -1.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BGM Group Ltd. has 16.4% gross margin and -2.2% operating margin.